{"id":6271,"date":"2002-01-09T23:30:36","date_gmt":"2002-01-09T22:30:36","guid":{"rendered":"http:\/\/moomango.co.uk\/htb\/?p=6271"},"modified":"2014-06-05T14:29:42","modified_gmt":"2014-06-05T14:29:42","slug":"impact-of-kaletra-on-amprenavir-plasma-concentrations-in-hiv-treatment-experienced-patients","status":"publish","type":"post","link":"https:\/\/i-base.info\/htb\/6271","title":{"rendered":"Impact of Kaletra on amprenavir plasma concentrations in HIV treatment-experienced patients"},"content":{"rendered":"<p><strong>Kaletra (lopinavir\/ritonavir) and amprenavir (APV) are both potent HIV protease inhibitors (PI) with demonstrated efficacy in salvage therapy. Few data are available on the combination of these two PIs and reciprocal drug-drug interaction remains unknown.<\/strong><\/p>\n<p>The objective of a French study presented at the 41st ICAAC was to assess APV and lopinavir\/r plasma concentrations of this combination, and to compare to APV and lopinavir\/r plasma concentrations with patients receiving only one of these PI.<\/p>\n<p>Plasma PI Cmin were determined in consecutive patients receiving lopinavir\/r (400\/100mg BID) (n=11), APV + Ritonavir (RTV) (600\/100mg BID) (n=36), lopinavir\/r (400\/100mg BID) + APV (600mg BID) (n=10), and lopinavir\/r (400\/100 mg BID) + APV (750 mg BID) (n=5).<\/p>\n<p>All patients received two nucleoside analogues associated with APV and\/or lopinavir\/r, but none efavirenz (Sustiva) or nevirapine (Viramune). All plasma concentrations were determined by HPLC.<\/p>\n<p><strong>Study results<\/strong><\/p>\n<p>APV median Cmin were 1755 ng\/ml [607-3066], 778 [190-2037], 998 [669-1670] in patients receiving APV+ RTV (600\/100 BID), lopinavir\/r + APV (600\/BID), and lopinavir\/r + APV (750 BID), respectively.<\/p>\n<p>Lopinavir (LPV) median Cmin were respectively 3326 ng\/ml [1316-6698], 2226 [518-8722] and 1716 [347-4810] in patients receiving lopinavir\/r, lopinavir\/r + APV 600 BID, lopinavir\/r +APV 750 BID.<\/p>\n<p>RTV median Cmin were 103 ng\/ml [34-366] , 147 [ 80-519] , 91 [10-1399] , 154 [ 30-203] in patients receiving respectively APV\/RTV , ABT 378\/r , and ABT 378\/ r + APV.<\/p>\n<p><strong>Conclusion<\/strong><\/p>\n<p>Plasma APV Cmin were decreased by more than 50% in patients receiving the combination of APV + lopinavir\/r with significant difference (p&lt;0.001 )in comparison with APV+ RTV (600\/100 BID). Nevertheless, APV Cmin remained &gt; 500 ng\/ml in all patients except one. The impact of this interaction on the clinical efficacy of the combination remains to be investigated.<\/p>\n<p>Reference:<\/p>\n<p>JL Meynard. Impact of ABT 378\/r on the Amprenavir (APV) Plasma Concentrations in HIV-Experienced Patients Treated by the Association APV -ABT 378\/r. Abstract I-1736 (poster).<\/p>\n<p>Source:<br \/>\n<a href=\"http:\/\/www.hivandhepatitis.com\/\">http:\/\/www.hivandhepatitis.com<\/a><\/p>\n<p>Copyright: HIV and hepatitis.com<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Kaletra (lopinavir\/ritonavir) and amprenavir (APV) are both potent HIV protease inhibitors (PI) with demonstrated efficacy in salvage therapy. Few data are available on the combination of these two PIs and reciprocal drug-drug interaction remains unknown. The objective of a French &hellip;<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4,3],"tags":[96],"class_list":["post-6271","post","type-post","status-publish","format-standard","hentry","category-conference-reports","category-antiretrovirals","tag-icaac-41st-2001"],"_links":{"self":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/6271","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/comments?post=6271"}],"version-history":[{"count":0,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/6271\/revisions"}],"wp:attachment":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/media?parent=6271"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/categories?post=6271"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/tags?post=6271"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}